Amylin reduces plasma glucagon concentration in cats

Veterinary Journal

Volumn 184, Issue 2, 2010, Pages 236-240

  Furrer, Daniela ^a   Kaufmann, K ^b   Reusch, Claudia E ^b   Lutz, Thomas A ^a  

^a VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Amylin; Cat; Diabetes mellitus; Glucagon

Indexed keywords

AMYLIN; GLUCAGON; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CAT DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; HORMONE ACTION; HYPERGLUCAGONEMIA; INSULIN BLOOD LEVEL; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROVOCATION TEST; STOMACH EMPTYING; TEST MEAL;

AMYLOID; ANIMALS; CAT DISEASES; CATS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC EMPTYING; GLUCAGON; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; RANDOM ALLOCATION;

ANIMALIA; FELIDAE; RATTUS;

EID: 77549088253     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2009.02.011     Document Type: Article

References (28)

1. Cefalu W.T. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. Institute for Laboratory Animal Research Journal 47 (2006) 186-198
2. Ceriello A., Colagiuri S., Gerich J., and Tuomilehto J. Guideline for management of postmeal glucose. Nutrition, Metabolism and Cardiovascular Diseases 18 (2008) S17-S33
3. Edelman S.V., and Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second ß-cell hormone. Diabetes Technology and Therapeutics 4 (2002) 175-189
4. Fineman M., Weyer C., Maggs D.G., Strobel S., and Kolterman O.G. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Hormone and Metabolic Research 34 (2002) 504-508
5. Henson M.S., and O'Brien T.D. Feline models of type 2 diabetes mellitus. Institute for Laboratory Animal Research Journal 47 (2006) 234-242
6. Hollander P.A., Levy P., Fineman M.S., Maggs D.G., Shen L.Z., Strobel S.A., Weyer C., and Kolterman O.G. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patient with type 2 diabetes. Diabetes Care 26 (2003) 784-790
7. Hollander P., Maggs D.G., Ruggles J.A., Fineman M., Shen L., Kolterman O.G., and Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity Research 12 (2004) 661-668
8. Johnson K.H., O'Brien T.D., and Betsholtz C. Islet amyloid, islet-amyloid polypeptide and diabetes mellitus. New England Journal of Medicine 321 (1989) 513-518
9. Johnson K.H., O'Brien T.D., Betsholtz C., and Westermark P. Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus. Laboratory Investigation 66 (1992) 522-535
10. Kitamura T., Yasuda J., and Hashimoto A. Acute insulin response to intravenous arginine in non-obese healthy cats. Journal of Veterinary Internal Medicine 13 (1999) 549-556
11. Ludvik B., Lell B., Hartter E., Schnack C., and Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40 (1991) 1615-1619
12. Lutz T.A. The pancreatic hormone amylin as a centrally acting satiating hormone. Current Drug Targets 6 (2005) 181-189
13. Lutz T.A., and Rand J.S. Pathogenesis of feline diabetes mellitus. Veterinary Clinics of North America Small Animal Practice 25 (1995) 527-552
14. Lutz T.A., and Rand J.S. Plasma amylin and insulin concentrations in normoglycemic and hyperglycaemic cats. Canadian Veterinary Journal 37 (1996) 27-34
15. Maggs D.G., Fineman M., Kornstein J., Burrell T., Schwartz S., Wang Y., Ruggles J.A., Kolterman O.G., and Weyer C. Pramlintide reduces postprandial glucose excursion when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes/Metabolism Research and Reviews 20 (2004) 55-60
16. O'Brien T.D., Westermark P., and Johnson K.H. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated and dexamethasone-treated rats. Diabetes 40 (1991) 1701-1706
17. Ratner R.E., Want L.L., Fineman M.S., Velte M.J., Ruggles J.A., and Gottlieb A. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technology and Therapeutics 4 (2002) 51-61
18. Seldinger S.I. Catheter replacement of the needle in percutaneous arteriography. Acta Radiologica 39 (1953) 368-376
19. Thompson R.G., Pearson L., Schoenfeld S.L., and Kolterman O.G. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 21 (1998) 987-993
20. Tschuor F., Furrer D., Kaufmann K., Lutz T.A., and Reusch C.E. Intravenous arginine stimulation test in cats with transient and non-transient diabetes mellitus. Journal of Veterinary Internal Medicine 20 (2006) 725-726
21. Vella A., Lee J.S., Camilleri M., Szarka L.A., Burton D.D., Zinsmeister A.R., Rizza R.A., and Klein P.D. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterology and Motility 14 (2002) 123-131
22. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 5036-5040
23. Weyer C., Maggs D.G., Young A.A., and Koltermann O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current Pharmaceutical Design 7 (2001) 1353-1373
24. Young A. Tissue expression and secretion of amylin. Amylin: physiology and pharmacology. Advances in Pharmacology 52 (2005) 19-46
25. Young A. Inhibition of insulin secretion. Amylin: physiology and pharmacology. Advances in Pharmacology 52 (2005) 173-192
26. Young A. Clinical studies. Amylin: physiology and pharmacology. Advances in Pharmacology 52 (2005) 289-320
27. Young A.A., Vine W., Gedulin B.R., Pittner R., Janes S., Gaeta L.S.L., Percy A., Moore C.X., Koda J.E., Rink T.J., and Beaumont K. Preclinical pharmacology of pramlintide in the rat: comparison with human and rat amylin. Drug Development Research 37 (1996) 231-248
28. Zini E., Osto M., Franchini M., Guscetti F., Donath M.Y., Perren A., Heller R.S., Linscheid P., Bouwman M., Ackermann M., Lutz T.A., and Reusch C.E. Hyperglycemia but not hyperlipidemia causes beta cell dysfunction and beta cell loss in the domestic cat. Diabetologia 52 (2009) 336-346 10.1007/s00125-008-1201-y